NCT05742022View on ClinicalTrials.gov

"Phospholipovit vs Placebo in Patients With Combined Hyperlipidemia"

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2016

Primary Completion Date

June 20, 2018

Study Completion Date

December 20, 2022

Conditions
Combined Hyperlipidemia
Interventions
DRUG

"Phospholipovit"

500 mg orally 2 times a day, for 12 weeks

DRUG

Placebo

500 mg orally 2 times a day, for 12 weeks

Trial Locations (3)

121552

"Federal State Budgetary Institution National Medical Research Centre Of Cardiology of the Ministry of Health of the Russian Federation", Moscow

150040

"LLC Medical Center for Diagnostics and prevention plus", Yaroslavl

603071

"LLC Nizhny Novgorod Medical clinic", Nizhny Novgorod

All Listed Sponsors
lead

Institute of Biomedical Chemistry, Russia

OTHER

NCT05742022 - "Phospholipovit vs Placebo in Patients With Combined Hyperlipidemia" | Biotech Hunter | Biotech Hunter